Henry Schein reports Q2 2026 results and raises guidance
Non-GAAP diluted EPS rose to $1.27 from $1.10; full-year EPS guidance increased to $5.29-$5.39.
See the latest news and media coverage for Henry Schein. We track all announcements, press releases, and industry mentions in real time, all in one place.
Healthcare products and services distributor
henryschein.comLast updated
In short: Henry Schein appointed Fred Lowery as CEO, reported strong 2026 financial growth, and restructured its executive leadership and board.
Non-GAAP diluted EPS rose to $1.27 from $1.10; full-year EPS guidance increased to $5.29-$5.39.
Company creates Henry Schein Leadership Team, three executives become senior advisors effective October 30, 2026.
Daniel succeeds Stanley M. Bergman, who retired after 44 years and was named Chairman Emeritus.
Net sales rose 6.3% to $3.4 billion. GAAP EPS increased to $0.92 from $0.88. Non-GAAP EPS rose to $1.32 from $1.15. Reaffirms 2026 guidance.
Henry Schein stock is trading on the back of a strong second quarter 2026 performance, with the Melville based health care distributor (ISIN US42548G1040) reporting...
Henry Schein, Inc. reported past Q2 2026 results with sales rising to US$3,458 million and net...
Dental and medical products company Henry Schein (NASDAQ:HSIC) reported Q2 CY2026 results topping th...
Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings...
Track Henry Schein and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.